Bolsas y Mercados Españoles
Company
search
PHARMA MAR, S.A.
AddressAV/ DE LOS REYES 1, 28770 COLMENAR VIEJO-MADRID 
Listed Capital11,132,464.35 Euros

 


PHARMA MAR
ISINES0169501030 TickerPHM Nominal0.05 MarketContinuous Market Admitted Capital11,132,464.35 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
03/07/2020Close9.31508.090015.149.31509.43008.24009.02676,596,97359,549,076.69
X
03/07/2020 17:37:08
BidAsk
OrdersVolumePricePriceVolumeOrders
12,3759.31509.32008,93412
29449.31009.330015,04111
11,0209.30509.33507,3466
64,6589.30009.340053,1734
11279.29509.34506462

Last pay
TypeEx-datePayment DateConcept
Dividend26/06/202030/06/2020Annual 2019

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
02/06/20172 x 1,000Premium


 2020
until 3/07
2019201820172016
Capitalisation *
(thousands of euros)
2,073,978794,858242,688552,170602,175
Shares
(x 1,000)
222,649222,649222,649222,649222,205
Period Close Price
(euros)
9.31503.57001.09002.48002.7100
Period Last Price
(euros)
9.31503.57001.09002.48002.7100
Period High Price
(euros)
9.43003.84602.76204.25503.1950
Period Low Price
(euros)
2.50001.07800.87102.03501.6900
Volume
(thousands of shares)
405,195321,427221,480205,284141,853
Turnover
(thousands of euros)
1,998,410650,774348,611654,106354,012

Profile

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program.

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM60184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom and the United States.

PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova and Xylazel.

To learn more about PharmaMar, please visit us at www.pharmamar.com.

 

Source: Issuing company.
04/07/2020 00:01:00

Research

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © BME 2020